Clinical Ovarian Cancer

Journal

Publication Venue For

  • The efficacy and toxicity of bevacizumab in combination with gemcitabine in patients with recurrent ovarian cancer.  4:34-37. 2011
  • CON: Patients at high risk for ovarian cancer should not undergo routine screening.  4:86-89. 2011
  • CON: Therapy for a patient with platinumresistant/refractory ovarian cancer should not be selected based on results of an in vitro extreme drug sensitivity/resistance assay.  4:57-61. 2011
  • PRO: Patients with recurrent ovarian cancer should be treated with antiangiogenic agents in combination with chemotherapy.  4:70-73. 2011
  • Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer.  3:81-97. 2010
  • The Gynecologic Oncology Group ovarian treatment trials with specimen banking and translational research.  3:98-112. 2010
  • The clinical impact of computed tomography immediately following primary chemotherapy in patients with epithelial ovarian cancer.  3:52-55. 2010
  • Debate: Treatment of patients with recurrent ovarian cancer should be treated with antiangiogenic agents in combination with chemotherapy.  2:12-15. 2009
  • Early-stage endometrial cancer: Is adjuvant radiation really warranted?.  2:90-93. 2009
  • Editorial: Getting personal: The treatment of epithelial ovarian cancer.  2:9-11. 2009
  • CON: Therapy for a patient with platinum-resistant/refractory ovarian cancer should not be selected based on results of an in vitro extreme drug sensitivity/resistance assay.  1:99-103. 2008
  • International Standard Serial Number (issn)

  • 1941-4390
  • Electronic International Standard Serial Number (eissn)

  • 1941-4404